Van Herk Groep

SkylineDx B.V. is a biotechnology company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests aimed at personalizing treatment in oncology. The company focuses on molecular diagnostics for blood cancers, offering tools such as the AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and the MMprofiler, a microarray-based service for diagnosing Multiple Myeloma. These diagnostics assist healthcare professionals in making informed therapy decisions tailored to individual patients. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance the development of companion diagnostics and other related tests. The company was founded in 2005 and was previously known as Skyline Diagnostics B.V. before rebranding in 2013.

SkylineDx B.V. is a biotechnology company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests aimed at personalizing treatment in oncology. The company focuses on molecular diagnostics for blood cancers, offering tools such as the AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and the MMprofiler, a microarray-based service for diagnosing Multiple Myeloma. These diagnostics assist healthcare professionals in making informed therapy decisions tailored to individual patients. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance the development of companion diagnostics and other related tests. The company was founded in 2005 and was previously known as Skyline Diagnostics B.V. before rebranding in 2013.

Ceradis B.V. is a company that specializes in the development and marketing of environmentally friendly solutions for plant nutrition and crop protection products. Founded in 2005 and based in Wageningen, the Netherlands, with an additional office in Bogotá, Colombia, Ceradis also offers crop formulation services. The company's products feature patented formulations that ensure optimal activity of ingredients and provide excellent handling characteristics for users. Ceradis serves the agricultural industry both in the Netherlands and on an international scale.

Medis is a provider of post-processing software for the quantification of cardiovascular images. Medis' mission is to empower medical professionals by providing software that gives them the facts.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Vastned is a retail property company based in the Netherlands that specializes in high-quality retail spaces in prominent locations across Europe. It focuses on investing in prime shopping venues in major cities, specifically targeting the Premium City High Street Shops segment. Vastned's portfolio is valued at approximately €1.5 billion and includes a diverse range of properties, primarily leased to leading international and national retail brands in sectors such as fashion, dining, and general retail. The company operates across various segments, with significant operations in the Netherlands, France, Belgium, and Spain, generating most of its rental income from these key markets.

Sensara B.V., based in Rotterdam, the Netherlands, specializes in home healthcare equipment and software through its product Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring their safety and well-being. Sensara utilizes self-learning algorithms to monitor medically verified profiles, analyzing data from various sensors and providing alerts, signals, and advice to family members or caregivers as needed. The information is accessible through user-friendly apps and interfaces, allowing clients to have control over their own data and privacy. Sensara's modular product line offers comprehensive solutions that cater to different living environments, from independent and assisted living to nursing homes, with the goal of enhancing care based on historical data.

NightBalance B.V., founded in 2009 and based in The Hague, the Netherlands, develops and markets innovative solutions for the treatment of positional obstructive sleep apnea (OSA). The company's primary product, the Sleep Position Trainer (SPT), continuously monitors a patient's sleep behavior and delivers gentle vibrations to prompt them to change their position when they turn onto their back, thereby minimizing disruptions to their natural sleep patterns. NightBalance originated from research conducted at Delft University of Technology, where efforts to enhance positional therapy for sleep apnea began in 2007. The company operates as a subsidiary of Koninklijke Philips N.V., focusing on improving patient comfort and sleep quality through its smart therapy solutions.

VBHC is a professionally managed real estate company with marquee investors. They are privileged that India's largest home financer, Housing Development Finance Corporation (HDFC), is an anchor equity investor in VBHC.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Isobionics B.V. develops, produces, and sells natural products for customers in flavor and fragrance market. It produces compounds, such as citrus oils that include lemon, orange, and grapefruit; compounds, including valencene and nootkatone, menthol, sandalwood oil, and patchouli oil; and other basic building blocks for the flavor and fragrance industry. The company was founded in 2008 and is based in Geleen, the Netherlands. As of September 26, 2019, Isobionics B.V. operates as a subsidiary of BASF SE.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

SkylineDx B.V. is a biotechnology company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests aimed at personalizing treatment in oncology. The company focuses on molecular diagnostics for blood cancers, offering tools such as the AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and the MMprofiler, a microarray-based service for diagnosing Multiple Myeloma. These diagnostics assist healthcare professionals in making informed therapy decisions tailored to individual patients. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance the development of companion diagnostics and other related tests. The company was founded in 2005 and was previously known as Skyline Diagnostics B.V. before rebranding in 2013.

NightBalance B.V., founded in 2009 and based in The Hague, the Netherlands, develops and markets innovative solutions for the treatment of positional obstructive sleep apnea (OSA). The company's primary product, the Sleep Position Trainer (SPT), continuously monitors a patient's sleep behavior and delivers gentle vibrations to prompt them to change their position when they turn onto their back, thereby minimizing disruptions to their natural sleep patterns. NightBalance originated from research conducted at Delft University of Technology, where efforts to enhance positional therapy for sleep apnea began in 2007. The company operates as a subsidiary of Koninklijke Philips N.V., focusing on improving patient comfort and sleep quality through its smart therapy solutions.

Vitalnext B.V., founded in 2013 and based in Amersfoort, the Netherlands, focuses on developing products that provide evidence-based health benefits for the aging population. The company offers a range of products, including Promanna, which comprises orally administered active small molecules; L-Proline, known for its positive effects on organisms under stress; D-Mannitol, a sugar with historical health benefits; and Vital01, designed to address malnutrition in the elderly. Vitalnext aims to enhance healthy aging, responding to the growing global demand for products that promote prolonged well-being. Their most advanced offering is an innovative medical nutrition product that not only helps improve body weight in malnourished individuals but also enhances body composition by increasing muscle mass. The company commercializes its products through distribution and licensing agreements with specialized partners, bridging the gap between life sciences and consumer health products.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.